GSK3B and diabetic kidney disease: For instance, inhibition of GSK3β by the selective small molecule inhibitor 6-bromoindirubin-3′-oxime (BIO) at a low dose dramatically normalized proteinuria and attenuated histologic injury of glomeruli in rat models of diabetic nephropathy, although hyperglycemia was not corrected, implying direct antiproteinuric and renoprotective action [31].